Research questions concerning hepatitis C virus: Report from a workshop at the Harvard Center for Cancer Prevention

Cancer Causes and Control

Volumn 10, Issue 6, 1999, Pages 485-487

  Cradock, Angie L ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGY; JAPAN; LIVER CELL CARCINOMA; LIVER TUMOR; PHYSIOLOGY; RESEARCH; RISK FACTOR; UNITED STATES; VIROLOGY; CARCINOGENESIS; DISEASE SEVERITY; HEMOPHILIA; IMMUNE RESPONSE; LIVER CIRRHOSIS; PATHOGENESIS; PRIORITY JOURNAL; SEROPREVALENCE; WORKSHOP;

CARCINOMA, HEPATOCELLULAR; HEPACIVIRUS; HEPATITIS C; HUMANS; JAPAN; LIVER NEOPLASMS; RESEARCH; RISK FACTORS; UNITED STATES;

INTERFERON;

EID: 0033254150     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008914103840     Document Type: Article

References (15)

1. Centers for Disease Control and Prevention (1998) Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morbid Mortal Wkly Rep 47: RR-19.
2. Tanaka K, Stuver SO, Ikematsu H, et al. (1997) Heterosexual transmission of hepatitis C virus among married couples in southwestern Japan. Int J Cancer 72: 50-55.
3. Alter MJ (1997) Epidemiology of hepatitis C. Hepatology 26(Suppl 1): 62S-65S.
4. Dienstag JL (1997) Sexual and perinatal transmission of hepatitis C. Hepatology 26(Suppl 1): 66S-70S.
5. Hoofnagle JH (1997) Hepatitis C: the clinical spectrum of disease. Hepatology 26(Suppl 1): 15S-20S.
6. Ikeda K, Saitoh S, Koida I, et al. (1993) A multivariate analysis of risk factors for hepatocellular carcongenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18: 47-53.
7. Ray RB, Steele R, Meyer K, Ray R (1997) Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 272: 10983-10986.
8. Kim DW, Suzuki R, Harada T, Saito I, Miyamura T (1994) Transsuppression of gene expression by hepatitis C viral core protein. Jpn J Med Sci Biol 47: 211-220.
9. Koziel MJ, Walker BD (1997) Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection. Springer Semin Immunopathol 19: 69-83.
10. Nelson DR, Marousis CG, Davis GL, et al. (1997) The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 158: 1473-1481.
11. Koziel MJ (1997) The role of immune responses in the pathogenesis of hepatitis C virus infection. J Viral Hepat 4(Suppl 2): 31-41.
12. Yano M, Kumada H, Kage M, et al. (1996) The long-term pathological evolution of chronic hepatitis. Hepatology 23: 1334-1340.
13. McHutchison JG, Gordon SC, Schiff ER, et al. (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339: 1485-1492.
14. Poynard T, Marcellin P, Lee SS, et al. (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 352: 1426-1432.
15. Fattovich G, Giustina G, Degos F, et al. (1997) Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112: 463-472.